Terumo (TRUMY) Stock Rating Lowered by Zacks Investment Research

Terumo (OTCMKTS:TRUMY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Terumo Corporation is engaged in the manufacture and sales of medical products and equipment. The products offered by the Company covers General Hospital Products, Cardiac & Vascular Products, Blood Transfusion Products and Consumer Healthcare Products. General hospital products offered by it include Disposable Medical Equipment, Medical Electronic Products, Diabetes Care Products, CAPD Systems and Pharmaceuticals; Cardiac & Vascular Products include Interventional Systems, Cardiovascular Systems and Artificial Vascular Grafts. Terumo’s Blood Transfusion products include blood bags, blood filter, filter in line, blood administration sets and apheresis, while consumer healthcare products include ear thermometer, electronic thermometer, basal body thermometer, electronic sphygmomanometer, urine test strip and leg compression stockings. Terumo Corporation is headquartered in Tokyo, Japan. “

Terumo (OTCMKTS TRUMY) opened at $46.75 on Wednesday. Terumo has a twelve month low of $33.90 and a twelve month high of $48.39. The firm has a market cap of $17,753.83, a PE ratio of 39.62 and a beta of 0.20.

COPYRIGHT VIOLATION NOTICE: This news story was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/12/08/terumo-trumy-stock-rating-lowered-by-zacks-investment-research.html.

Receive News & Ratings for Terumo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply